Core Insights - Sodexo reported consolidated revenues of 6.1 billion euros for Q3 Fiscal 2025, reflecting a year-on-year increase of 0.8%, with organic revenue growth of 3.0% [5][16] - The company expects Fiscal 2025 organic revenue growth to be at the lower end of the guidance range, between 3% and 4% [4][12] - The CEO emphasized the importance of disciplined execution and strengthening client relationships to achieve sustainable growth [2] Revenue Breakdown - **North America**: Revenues reached 2.9 billion euros, with organic growth of 1.2%. This growth was driven by pricing momentum and new business, despite contract exits impacting overall performance [5][17] - **Europe**: Revenues totaled 2.2 billion euros, showing an organic growth of 3.3%, supported by strong performance in Healthcare & Seniors and Sodexo Live! [5][23] - **Rest of the World**: Revenues amounted to 1.1 billion euros, with organic growth of 7.5%, primarily driven by strong performance in India, Brazil, and Australia [5][26] Financial Position and Activities - Sodexo successfully issued U.S. dollar notes totaling $1.1 billion to fund the repurchase of existing senior notes [5] - The company completed the acquisition of Agap'pro, enhancing its procurement capabilities in the hospitality sector [5] - Sodexo received an A- score from CDP for climate change disclosure, indicating strong leadership in environmental responsibility [5] Currency Impact - The company experienced a negative currency impact of 2.1% in Q3, mainly due to the depreciation of the U.S. dollar and several Latin American currencies [5][32] Outlook - The company anticipates landing towards the lower end of the range for both organic growth and underlying operating margin for Fiscal 2025 [7]

Affirm Holdings (NASDAQ: AFRM ) is a fast-growing player in the Buy Now, Pay Later market and is nearing a crucial inflection point in its business, which is the achievement of GAAP operating profitability in the near term. Further, Affirm may be aAnalyst’s Disclosure:I/we have a beneficial long position in the shares of AFRM, UPST, SOFI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other ...

Investment Rating - The investment rating for Meiji Holdings is Neutral, with a 12-month target price revised to ¥3,400 from ¥3,500, reflecting a slight decrease in operating profit estimates [1][18][22]. Core Insights - The report indicates that operating profits for FY3/25 are expected to miss guidance, primarily due to anticipated shortfalls in sales across domestic milk, the dairy overseas business, and the vaccines/animal health business [1][17]. - The company has a significant market share in Japan for dairy products, chocolate, and protein products, but its growth prospects are considered to be adequately reflected in the current share price [22]. - The report highlights the importance of monitoring input costs, price hikes, and sales recovery in the food segment, as well as growth in the pharmaceuticals segment, particularly in vaccines and overseas business expansion [19][22]. Financial Estimates - FY3/26 operating profit estimates have been adjusted by -0.1% for the overall company, with specific adjustments of +¥0.7 billion for the food segment and +¥0.2 billion for the pharmaceuticals segment, while adjustments account for a decrease of -¥1.0 billion [1][17]. - Sales estimates for FY3/26 are projected at ¥1,192.2 billion, reflecting a year-on-year growth of 3.3% [3][20]. - The net profit for FY3/26 is estimated at ¥53.9 billion, with an EPS of ¥202.1 [3][20]. Segment Performance - The food segment's operating profit is expected to be ¥70.7 billion for FY3/26, while the pharmaceuticals segment is projected at ¥25.7 billion [20]. - Key areas of focus for the food segment include dairy, chocolate, and nutrition, with specific sales estimates for dairy at ¥273.5 billion and chocolate at ¥177.2 billion for FY3/26 [20]. - The pharmaceuticals segment is anticipated to see growth driven by vaccines and the expansion of the overseas CMO/CDMO business, despite challenges from drug price revisions [19][22].

Entravision Communications (EVC) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Roy Nir - VP of Financial and IRMichael Christenson - Chief Executive OfficerMark Boelke - CFO & Treasurer Operator Greetings, and welcome to the Intravision First Quarter twenty twenty five Earnings Conference Call. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Roynier. Please go ahead. Roy Nir Good afternoon everyone and welcome to Entravision's first quart ...

Core Viewpoint - Lassonde Industries Inc. reported strong financial results for Q1 2025, with significant growth in sales and operating profit despite ongoing market uncertainties [3][4]. Financial Performance - Sales reached $699.7 million, an increase of $129.8 million (22.8%) compared to $569.8 million in Q1 2024 [2]. - Gross profit was $183.2 million, representing 26.2% of sales, up from $149.6 million, a rise of $33.6 million (22.4%) year-over-year [2][4]. - Operating profit increased to $42.7 million, up $8.1 million (23.4%) from $34.6 million in the same quarter last year [2][4]. - Profit attributable to shareholders was $24.5 million, slightly up from $23.8 million, with an EPS of $3.60, reflecting a 2.9% increase [2][7]. - Adjusted EBITDA was $71.5 million, a rise of $19.1 million (36.4%) from $52.4 million in Q1 2024 [2][7]. Sales Growth Drivers - Excluding the impact of Summer Garden and foreign exchange fluctuations, sales grew by 9.3%, driven by U.S. volume recovery and price adjustments in Canada [3][4]. - Canadian brands gained market share due to innovation and effective merchandising, despite overall industry volume contraction [3]. Outlook and Strategy - The company anticipates a sales growth rate of approximately 10% for 2025, driven by a full year of Summer Garden results and planned price adjustments [8]. - Lassonde is focused on executing its strategy, expanding capacity, and leveraging its diversified product portfolio to enhance its presence in the North American food and beverage market [3][8]. Financial Position - As of March 29, 2025, total assets were $2,374.4 million, a 4.2% increase from $2,277.8 million at the end of 2024 [7]. - Long-term debt stood at $612.5 million, with a net debt to adjusted EBITDA ratio of 1.99:1, reflecting a $135.0 million increase from the previous year [7][26]. - Operating activities used $60.1 million in cash, compared to $11.3 million generated in the same quarter last year, primarily due to changes in working capital [7]. Dividend Information - The Board of Directors declared a quarterly dividend of $1.10 per share, payable on June 13, 2025 [17]. Company Overview - Lassonde Industries Inc. is a leader in the North American food and beverage industry, offering a wide range of products including fruit juices, specialty foods, and snacks [28][30].

Sanuwave Health (SNWV) Q3 2024 Earnings Call November 08, 2024 08:30 AM ET Speaker0 Please note this call is being recorded and I will be standing by if you should need any assistance. It is now my pleasure to turn the conference over to Morgan Frank, Chairman and CEO of Sanywave. Speaker1 Thank you very much. So welcome, everyone, to Sanywave's third quarter twenty twenty four earnings call. As many of you saw, our Form 10 Q was filed with the SEC last night. Our earnings release was issued this morning, a ...